Full Press Release Details
Accelerate Diagnostics Reports Second Quarter
2021 Financial Results
TUCSON, Ariz., August 5, 2021 -- Accelerate Diagnostics, Inc. (Nasdaq:
AXDX) today announced financial results for the second quarter for the period ended June 30, 2021.
"Second quarter and year to date financial results were consistent
with our expectations," commented Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc. "We also launched
our AST focused test kit, concluded our multi-hospital registry study with compelling new data, and advanced other key commercial and
product development priorities during the quarter."
Second Quarter 2021 Highlights
Year-to-date 2021 Highlights
Full financial results for the quarter ending June 30, 2021 will be
filed on Form 10-Q through the Securities and Exchange Commission's (SEC) website at http://www.sec.gov.
Audio Webcast and Conference Call
To listen to the 2021 second quarter financial results, call by phone,
+1.877.883.0383 and enter Elite Entry Number: 5467079. International participants may dial +1.412.902.6506. Please dial in 10-15
minutes prior to the start of the conference. A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088
(International) using the replay code 10157979 until August 26, 2021.
This conference call will also be webcast and can be accessed from
the company's website at ir.axdx.com. A replay of the audio webcast will be available until November 5, 2021.
Use of Non-GAAP Financial Measures
This press release contains certain financial
measures that are not recognized measures under accounting principles generally accepted in the United States of America ("GAAP"),
which include SG&A, R&D, and Net income (loss) amounts excluding stock-based compensation expenses.
Our management and board of directors use
expenses excluding the cost of stock-based compensation to understand and evaluate our operating performance and trends, to prepare and
approve our annual budget and to develop short-term and long-term operating and financing plans. Accordingly, we believe that expenses
excluding the cost of stock-based compensation provides useful information for investors in understanding and evaluating our operating
results in the same manner as our management and our board of directors. Expenses excluding the cost of stock-based compensation is a
non-GAAP financial measure and should be considered in addition to, not as superior to, or as a substitute for, SG&A expenses, R&D
expenses, and net income (loss) reported in accordance with GAAP. The following tables present a reconciliation of SG&A expenses,
R&D expenses and net income (loss) excluding stock-based compensation to comparable GAAP measures for the periods indicated:
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Sales, general and administrative | $ | 12,910 | $ | 11,332 | $ | 26,938 | $ | 24,275 | ||||||||
| Non-cash equity-based compensation as a component of sales, general and administrative | 5,188 | 3,022 | 11,180 | 6,027 | ||||||||||||
| Sales, general and administrative less non-cash equity-based compensation | $ | 7,722 | $ | 8,310 | $ | 15,758 | $ | 18,248 |
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Research and development | $ | 5,733 | $ | 5,347 | $ | 12,629 | $ | 11,189 | ||||||||
| Non-cash equity-based compensation as a component of research and development | 1,328 | 335 | 4,074 | 1,458 | ||||||||||||
| Research and development less non-cash equity-based compensation | $ | 4,405 | $ | 5,012 | $ | 8,555 | $ | 9,731 |
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Loss from operations | $ | (17,590 | ) | $ | (15,725 | ) | $ | (37,616 | ) | $ | (33,455 | ) | ||||
| Non-cash equity-based compensation as a component of loss from operations | 6,590 | 3,416 | 15,429 | 7,615 | ||||||||||||
| Loss from operations less non-cash equity-based compensation | $ | (11,000 | ) | $ | (12,309 | ) | $ | (22,187 | ) | $ | (25,840 | ) |
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in
vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate
Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians
must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample
preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures.
Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize
antibiotic selection and dosage specific to the individual patient days earlier.
The "ACCELERATE DIAGNOSTICS"
and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered
trademarks of Accelerate Diagnostics, Inc.
For more information about the company,
its products and technology, or recent publications, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press
release are forward looking or may have forward looking implications. Actual results or developments may differ materially from those
projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics
is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the
Securities and Exchange Commission on March 2, 2021, and in any other reports that the company files with the Securities and Exchange
Commission. The company's forward-looking statements could be affected by general industry and market conditions. Except as required by
federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events,
uncertainties or other contingencies.
For further information: Investor Inquiries & Media Contact: Laura
Pierson, Accelerate Diagnostics, +1 520 365-3100, investors@axdx.com
Source: Accelerate Diagnostics Inc.
ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
(in thousands, except share data)
| June 30, | December 31, | |||||||
| 2021 | 2020 | |||||||
| Unaudited | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 44,580 | $ | 35,781 | ||||
| Investments | 24,251 | 32,488 | ||||||
| Trade accounts receivable | 2,114 | 1,550 | ||||||
| Inventory | 9,572 | 9,216 | ||||||
| Prepaid expenses | 1,680 | 1,172 | ||||||
| Other current assets | 1,498 | 1,780 | ||||||
| Total current assets | 83,695 | 81,987 | ||||||
| Property and equipment, net | 5,548 | 6,135 | ||||||
| Right of use assets | 2,848 | 3,183 | ||||||
| Other non-current assets | 1,898 | 2,120 | ||||||
| Total assets | $ | 93,989 | $ | 93,425 | ||||
| LIABILITIES AND STOCKHOLDERS ' DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,877 | $ | 1,290 | ||||
| Accrued liabilities | 3,832 | 2,991 | ||||||
| Accrued interest | 1,262 | 1,262 | ||||||
| Deferred revenue | 282 | 376 | ||||||
| Current portion of long-term debt | 1,452 | 553 | ||||||
| Current operating lease liability | 612 | 497 | ||||||
| Total current liabilities | 9,317 | 6,969 | ||||||
| Non-current operating lease liability | 2,747 | 3,063 | ||||||
| Other non-current liabilities | 580 | 335 | ||||||
| Long-term debt | 3,805 | 4,659 | ||||||
| Convertible notes | 147,290 | 141,211 | ||||||
| Total liabilities | $ | 163,739 | $ | 156,237 | ||||
| Commitments and contingencies | ||||||||
| Stockholders' deficit: | ||||||||
| Preferred shares, $0.001 par value; | ||||||||
| 5,000,000 preferred shares authorized and none outstanding as of June 30, 2021 and December 31, 2020 | - | - | ||||||
| Common stock, $0.001 par value; | ||||||||
| 100,000,000 common shares authorized with 61,489,475 shares issued and outstanding on June 30, 2021 and 85,000,000 common shares authorized with 57,607,939 shares issued and outstanding on December 31, 2020 | 61 | 58 | ||||||
| Contributed capital | 514,122 | 475,072 | ||||||
| Treasury stock | (45,067 | ) | (45,067 | ) | ||||
| Accumulated deficit | (538,879 | ) | (492,966 | ) | ||||
| Accumulated other comprehensive income (loss) | 13 | 91 | ||||||
| Total stockholders' deficit | (69,750 | ) | (62,812 | ) | ||||
| Total liabilities and stockholders' deficit | $ | 93,989 | $ | 93,425 |
See accompanying notes to condensed consolidated
financial statements.
ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | June 30, | June 30, | |||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Net sales | $ | 2,798 | $ | 2,125 | $ | 5,316 | $ | 4,468 | ||||||||
| Cost of sales | 1,745 | 1,171 | 3,365 | 2,459 | ||||||||||||
| Gross profit | 1,053 | 954 | 1,951 | 2,009 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Research and development | 5,733 | 5,347 | 12,629 | 11,189 | ||||||||||||
| Sales, general and administrative | 12,910 | 11,332 | 26,938 | 24,275 | ||||||||||||
| Total costs and expenses | 18,643 | 16,679 | 39,567 | 35,464 | ||||||||||||
| Loss from operations | (17,590 | ) | (15,725 | ) | (37,616 | ) | (33,455 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense | (4,177 | ) | (3,835 | ) | (8,267 | ) | (7,584 | ) | ||||||||
| Foreign currency exchange gain (loss) | - | 91 | (159 | ) | (37 | ) | ||||||||||
| Interest income | 12 | 224 | 55 | 604 | ||||||||||||
| Other income (expense), net | 81 | 15 | 74 | (67 | ) | |||||||||||
| Total other expense, net | (4,084 | ) | (3,505 | ) | (8,297 | ) | (7,084 | ) | ||||||||
| Net loss before income taxes | (21,674 | ) | (19,230 | ) | (45,913 | ) | (40,539 | ) | ||||||||
| Provision for income taxes | - | - | - | - | ||||||||||||
| Net loss | $ | (21,674 | ) | $ | (19,230 | ) | $ | (45,913 | ) | $ | (40,539 | ) | ||||
| Basic and diluted net loss per share | $ | (0.36 | ) | $ | (0.35 | ) | $ | (0.77 | ) | $ | (0.74 | ) | ||||
| Weighted average shares outstanding | 61,049 | 55,445 | 59,790 | 55,139 | ||||||||||||
| Other comprehensive loss: | ||||||||||||||||
| Net loss | $ | (21,674 | ) | $ | (19,230 | ) | $ | (45,913 | ) | $ | (40,539 | ) | ||||
| Net unrealized (loss) gain on debt securities available-for-sale | - | (44 | ) | (18 | ) | 179 | ||||||||||
| Foreign currency translation adjustment | 22 | 34 | (60 | ) | 19 | |||||||||||
| Comprehensive loss | $ | (21,652 | ) | $ | (19,240 | ) | $ | (45,991 | ) | $ | (40,341 | ) |
See accompanying notes to condensed consolidated
financial statements.
ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS
| Six Months Ended | ||||||||
| June 30, | June 30, | |||||||
| 2021 | 2020 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (45,913 | ) | $ | (40,539 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 1,248 | 1,571 | ||||||
| Amortization of investment discount | 97 | 13 | ||||||
| Equity-based compensation | 15,429 | 7,615 | ||||||
| Amortization of debt discount and issuance costs | 6,079 | 5,426 | ||||||
| (Gain) loss on disposal of property and equipment | (100 | ) | 527 | |||||
| Contributions to deferred compensation plan | (236 | ) | (160 | ) | ||||
| (Increase) decrease in assets: | ||||||||
| Accounts receivable | (539 | ) | 550 | |||||
| Inventory and instruments in property and equipment | (524 | ) | (1,979 | ) | ||||
| Prepaid expense and other | 35 | (360 | ) | |||||
| Increase (decrease) in liabilities: | ||||||||
| Accounts payable | 564 | 390 | ||||||
| Accrued liabilities, and other | 736 | (581 | ) | |||||
| Accrued interest | 45 | - | ||||||
| Deferred revenue and income | (94 | ) | (39 | ) | ||||
| Deferred compensation | 245 | 171 | ||||||
| Net cash used in operating activities | (22,928 | ) | (27,395 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchases of equipment | (29 | ) | (643 | ) | ||||
| Purchase of marketable securities | (15,699 | ) | (21,509 | ) | ||||
| Maturities of marketable securities | 23,992 | 27,844 | ||||||
| Net cash provided by investing activities | 8,264 | 5,692 | ||||||
| Cash flows from financing activities: | ||||||||
| Proceeds from issuance of common stock | 22,283 | 216 | ||||||
| Proceeds from exercise of options | 1,222 | 3,031 | ||||||
| Proceeds from debt | - | 4,791 | ||||||
| Net cash provided by financing activities | 23,505 | 8,038 | ||||||
| Effect of exchange rate on cash | (42 | ) | 19 | |||||
| Increase (decrease) in cash and cash equivalents | 8,799 | (13,646 | ) | |||||
| Cash and cash equivalents, beginning of period | 35,781 | 61,014 | ||||||
| Cash and cash equivalents, end of period | $ | 44,580 | $ | 47,368 |
See accompanying notes to condensed consolidated
financial statements.
ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS (CONTINUED)
| Six Months Ended | ||||||||
| June 30, | June 30, | |||||||
| 2021 | 2020 | |||||||
| Non-cash investing activities: | ||||||||
| Net transfer of instruments from inventory to property and equipment | $ | 500 | $ | 1,288 | ||||
| Supplemental cash flow information: | ||||||||
| Interest paid | $ | 2,144 | $ | 2,144 | ||||
| Income taxes paid, net of refunds | $ | - | $ | 26 |
See accompanying notes to condensed consolidated
financial statements.